奧米加干擾素
Interferon Omega
Recombinant Omega Interferon of Feline Origin, rFelFN-w
別名: Virbagen Omega · interferon-w · IFN-w (feline recombinant) · rFelFN-w · rFeIFN-omega · Feline interferon omega
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Treatment of parvovirus (enteric form) | 2.5 million Units/kg IV once daily | IV | q24h | 3 days | 🌎 NA |
| Treatment of atopic dermatitis | Dogs 8-15 kg = 1 million Units; 15-29 kg = 2 million Units; 29-40 kg = 3 million Units; >40 kg = 4 million Units | SC | Specific days | Days 0, 3, 7, 14, 21, 35, 56, 90, 120, & 150 | 🌎 NA |
| Parvovirus | 2.5 million units/kg | IV | q24h | 3 days | 🌍 EU |
- Treatment of parvovirus (enteric form): The earlier the dog is treated, the more likely of success.
- Treatment of atopic dermatitis: Further larger-scale studies needed to confirm cost-effectiveness and safety for long-term treatment.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Treatment of FeLV and/or FIV (non-terminal clinical stages) | 1 million Units/kg SC once daily | SC | q24h | 5 days (Three separate 5-day treatments performed at day 0, day 14, and day 60) | 🌎 NA |
| FHV-1 facial dermatitis | Day 0: 1.5 million Units/kg (half peri-lesionally/intradermally, half SC). Day 2 and 9: 1.5 million Units/kg SC. Days 19, 21, and 23: 0.75 million Units/kg peri-lesionally/intradermally + 0.75 million Units/kg SC. | SC / Intradermal / Peri-lesional | Specific days | 23 days | 🌎 NA |
- FHV-1 facial dermatitis: Cat was sedated with propofol for peri-lesional and intradermal injections.
劑量為合格獸醫專業人員的臨床參考。請務必對照最新仿單及個別病患確認。
概覽
奧米加干擾素（Interferon-omega）是一種源自貓的重組第一型干擾素，具有強效的免疫調節與抗病毒作用。
- 獸醫應用：主要用於治療嚴重的病毒感染，特別是犬小病毒（Canine Parvovirus）與貓反轉錄病毒（貓白血病 FeLV 與貓愛滋 FIV）。
- 跨物種療效：臨床要點： 雖然它是貓源性蛋白質，但由於第一型干擾素具有跨物種的受體親和力，因此對狗也非常有效。然而，狗若長期使用可能會產生中和抗體。
- 新興應用：在治療犬異位性皮膚炎、貓傳染性腹膜炎（FIP）、貓卡里西病毒（FCV）以及貓疱疹病毒（FHV-1）引起的皮膚炎或角膜炎方面，已顯示出潛在益處。
- 取得方式：在歐盟及其他地區有商業販售，但在美國尚未上市（需透過恩慈療法合法專案進口）。
作用機轉
Interferon-omega does not act as a direct virucidal agent. Instead, it induces an antiviral state in host cells:
- Receptor Binding: Binds to specific type I interferon receptors on the surface of target cells.
- Signal Transduction: Activates the JAK-STAT signaling pathway.
- Gene Transcription: Induces the transcription of interferon-stimulated genes (ISGs).
- Antiviral Proteins: Leads to the production of key enzymes such as 2'-5' oligoadenylate synthetase (OAS) and protein kinase R (PKR).
- Viral Inhibition: These enzymes inhibit viral mRNA translation and degrade viral RNA → effectively halting viral replication.
Additionally, it nonspecifically enhances host immune defense mechanisms by stimulating natural killer (NK) cells and macrophages.
安全性與警告
禁忌症
- Concurrent vaccination in dogs (wait until fully recovered)
- Vaccination in cats during and after treatment (due to the immunosuppressive nature of FeLV/FIV)
- Substitution with human interferons (alpha, beta, or gamma)
- No specific contraindications available in the monograph
不良反應
- Hyperthermia (typically 3-6 hours post-dose)
- Vomiting
- Soft feces or mild diarrhea (cats)
- Transient fatigue or lethargy (cats)
- Slight decreases in RBCs, WBCs, and platelets (usually resolves within a week)
- Increased ALT (usually resolves within a week)
- Antibody formation in dogs (with prolonged or repeated treatment)
- Mild diarrhoea
- Decreased WBCs (leukopenia)
- Decreased platelets (thrombocytopenia)
- Decreased RBCs (anaemia)
- Increased liver enzyme activities
- Ocular irritation (with topical use in cats)
- Immune-mediated diseases (reported with long-term administration in humans)
注意事項
Do not vaccinate dogs currently being treated until they have fully recovered. Cat vaccinations are contraindicated during and after treatment due to the underlying immunosuppressive retroviral infections. Intravenous administration in cats may cause an increased incidence and severity of adverse effects, though adverse effects in cats are generally uncommon. Dogs may develop neutralizing antibodies if treatment is prolonged beyond the labeled dosage period.
藥物交互作用
May increase the risk of liver toxicity; use with caution.
May increase the risk of bone marrow suppression; use with caution.
Should not be administered concurrently until the animal has clinically recovered.
Improves prognosis; no negative interactions observed.
Improves prognosis; no negative interactions observed.
監測
- Clinical efficacy (resolution of viral infection signs)
- Complete Blood Count (CBC) to monitor for myelosuppression
- Hepatic function tests (ALT)
- Complete Blood Count (WBCs, RBCs, platelets)
- Liver enzyme activities
- Body temperature
- Clinical signs of gastrointestinal upset or fatigue
藥物動力學
半衰期
吸收
Rapidly bound to specific receptor sites on a variety of cells after intravenous injection.
分佈
Highest tissue levels are found in the liver and kidneys. In dogs, volume of distribution (Vd) at steady state is about 0.1 L/kg.
代謝
Catabolized in the kidneys.
排除
Filtered in the renal glomeruli. Total body clearance in dogs is 6.9 mL/min/kg.
過量
In safety studies, 10X overdoses in dogs and cats caused mild lethargy/somnolence, slight hyperthermia, and slight increases in respiratory and heart rates. In all animals tested, clinical signs resolved within 7 days and no specific treatment was required.
可用產品
劑型
- Lyophilized powder for injection: 10 million Units/vial
- Lyophilized powder for injection: 5 million Units/vial
- 10 million units/vial powder with solvent for reconstitution
獸醫用
- Virbagen Omega 10 million Units/vial
- Virbagen Omega 5 million Units/vial
各地核准狀態
Authorized for veterinary use in the EU.
POM-V classification.
暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Store in its original carton in the refrigerator (4°C ± 2°C) and protect from freezing. Shelf life is 2 years when properly stored. Once reconstituted with the supplied isotonic sodium chloride solution, it contains no preservatives and should ideally be used immediately; however, the reconstituted solution is reported to be stable for at least 3 weeks when refrigerated. Do not mix with any other vaccine or immunological product.
飼主須知
重要提示： 此藥物通常在動物醫院內給藥，以便獸醫能密切監測並提供支持性治療，特別是因為它常被用於治療如犬小病毒等嚴重的病毒感染。
- 預期反應：您的寵物在注射後 3 到 6 小時內可能會出現輕微發燒。這是免疫系統對藥物的正常反應。也可能出現輕微嘔吐、疲倦或軟便。
- 疫苗接種：在接受此治療期間，請勿讓您的寵物接種疫苗。對於感染 FeLV 或 FIV 的貓咪，由於其免疫系統受損，通常在治療後也不建議接種疫苗。
- 費用：奧米加干擾素的治療涉及先進的重組技術，費用可能非常高昂。請與您的獸醫師討論預期費用及預後情況。
VetSheet 藥物參考供合格獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠商最新仿單。